Related Experiment Video
Updated: Nov 23, 2025
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models
Daehyun Kim1,2,3, Seung Soo Lee3, Hyungwon Moon3
1Department of Nano Science and Technology, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Korea.
Abstract:
Cancer immunotherapy has revolutionized the way different neoplasms are treated. Among the different variations of cancer immunotherapy, the checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis have been validated and are currently used in the clinics. Nevertheless, these therapeutic antibodies are associated with significant side effects and are known to induce immune-related toxicities. To address these issues, we have developed an immune-microbubble complex (IMC) which not only reduces the toxicities associated with the antibodies but also enhances the therapeutic efficacy when combined with focused ultrasound. The concept of IMCs could be applied to any type of antibody-based treatment regimens to maximize their therapeutic potential.
Insights
Researchers developed an immune-microbubble complex (IMC) to improve cancer immunotherapy. This approach reduces toxicities from antibody treatments and enhances efficacy when combined with focused ultrasound, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Immunology
- Biomedical Engineering
Background:
- Cancer immunotherapy, particularly checkpoint inhibitors targeting the PD-1/PD-L1 axis, has transformed cancer treatment.
- Current antibody-based therapies can cause significant immune-related toxicities.
- There is a need for strategies to mitigate side effects and improve therapeutic outcomes.
Purpose of the Study:
- To develop a novel approach to reduce toxicities associated with cancer immunotherapy antibodies.
- To enhance the therapeutic efficacy of antibody-based cancer treatments.
- To explore the potential of immune-microbubble complexes (IMCs) combined with focused ultrasound.
Main Methods:
- Development of an immune-microbubble complex (IMC).
- Evaluation of IMCs for reducing antibody-associated toxicities.
- Combination therapy using IMCs and focused ultrasound to assess therapeutic efficacy.
Main Results:
- The developed IMC effectively reduced toxicities linked to therapeutic antibodies.
- Combining IMCs with focused ultrasound demonstrated enhanced therapeutic efficacy.
- The IMC approach shows promise for improving cancer treatment outcomes.
Conclusions:
- Immune-microbubble complexes offer a promising strategy to mitigate immunotherapy-related toxicities.
- The combination of IMCs and focused ultrasound can significantly enhance cancer treatment efficacy.
- This novel platform has broad applicability for antibody-based therapies in oncology.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023